Interventions in the management of serum lipids for preventing stroke recurrence

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Manktelow, Bradley N ^a   Potter, John F ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Antilipemic agents *therapeutic use ; Cardiovascular diseases prevention control ; Clofibrate therapeutic use ; Estrogens, conjugated (USP) therapeutic use ; Humans; Pravastatin therapeutic use ; Recurrence; Stroke *prevention control

Indexed keywords

ACIPIMOX; ANTILIPEMIC AGENT; ATORVASTATIN; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; CONJUGATED ESTROGEN; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PLACEBO; PRAVASTATIN; SIMVASTATIN;

BLEEDING; BRAIN IARCTION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DISEASE REGISTRY; DRUG INDUSTRY; HUMAN; LIPID BLOOD LEVEL; MORTALITY; OUTCOME ASSESSMENT; PUBLICATION; PUBLISHING; RECURRENT DISEASE; REVIEW; STROKE; SUDDEN DEATH; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

EID: 70049110201     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002091.pub2     Document Type: Review

References (59)

1. Acheson J, Hutchinson EC. A controlled trial of atromid in cerebral vascular disease. A preliminary report. Journal of Atherosclerosis Research 1963;3:711-715
2. * Acheson J, Hutchinson EC. Controlled trial of clofibrate in cerebral vascular disease. Atherosclerosis 1972;15:177-183
3. * Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, et al.Reduction of stroke incidence aftermyocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) Study. Circulation 1999;99(2):216-223 [MEDLINE: 99110724]
4. Sacks FM, Pfeffer MA, Moye L, Brown LE, Hamm P, Cole TG, et al.Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events Trial (CARE). American Journal of Cardiology 1991;68:1436-1446
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine 1996;335:1001-1009 (Pubitemid 26338729)
6. Kennedy J, Eliasziw M, Hill MD, Buchan AM. The Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER) Trial. Seminars in Cerebrovascular Diseases and Stroke 2003;3(1):25-30.
7. * Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurology 2007;6:961-969
8. MRC/BHF Heart Protection Study. http://www.ctsu.ox.ac.uk/~hps/.
9. Collins R, Peto R. MRC/BHF Heart Protection Study. Stroke 1994;25(2):543.
10. * Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-767
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
12. Heart Protection Study Collaborative Group. The MRC/BHF Heart Protection Study: preliminary results. International Journal of Clinical Practice 2002;56(1):53-56
13. MRC/BHF Heart Protection Study. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experence. European Heart Journal 1999;20:725-741
14. Kirby A. Personal communication. Unpublished. The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002;359:1379-1387
15. * White HD, Simes J, Anderson NE, Hankey GJ, Watson JDG, Hunt D, et al.Pravastatin therapy and the risk of stroke. New England Journal of Medicine 2000;343(5):317-326
16. Amarenco P, Bogousslavsky J, Callahan A, Goldstein L, Hennerici M, Sillesen H, et al.Effect of atorvastatin compared with placebo on cerebrovascular end points in patients with previous stroke or transient ischemic attack - The SPARCL Study. Cerebrovascular Diseases 1999;9 Suppl 1:108.
17. SPARCL Investigators. Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Cerebrovascular Diseases 2003;16:389-395
18. * SPARCL Investigators. High-dose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine 2006;355(6):549-559 [MEDLINE: 16899775]
19. Welch KMA. Stroke prevention by aggresive reduction in cholesterol levels (SPARCL). Stroke 2000;31(11):2541.
20. Hirsch SB, Wechsler AF, Tourtellotte WW. Clofibrate for the treatment of occlusive cerebrovascular disease. New England Journal of Medicine 1972;287(13):671. [MEDLINE: 73015139]
21. * The Veterans Administration Cooperative Study Group. The treatment of cerebrovascular disease with clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section. Stroke 1973;4:684-693 [MEDLINE: 73232915]
22. The Veterans Administration Cooperative Study of Atherosclerosis. An evaluation of estrogenic substances in the treatment of cerebral vascular disease. Circulation 1966;33(5 Suppl):II3-9. [MEDLINE: 91029891]
23. Kohriyama T, Nomura E, Matsumoto M, Ohtsuki T. J-STARS (Japan Statin Treatment Against Recurrent Stroke). Nippon Rinsho - Japanese Journal of Clinical Medicine 2006;64 Suppl 7:511-518
24. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of the American Medical Association 2002;288(23):2998-3007.
25. Sever PS, Dahlof B, Poulter NR, for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003;361:1149-1158 (Pubitemid 36398384)
26. Atkins D, Psaty BM, Koepsell TD, Longstreth WT, Larson EB. Cholesterol reduction and the risk for stroke inmen. Ameta-analysis of randomized, controlled trials. Annals of Internal Medicine 1993;199(2):136-145 [MEDLINE: 93290061] (Pubitemid 23286480)
27. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28(5):946-950 [MEDLINE: 97302269]
28. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Annals of Internal Medicine 1998;128(2):89-95. [MEDLINE: 98085833]
29. Butterworth RJ, Marshall WJ, Bath PMW. Changes in serum lipid measurements following acute ischemic stroke. Cerebrovascular Diseases 1997;7:10-13 (Pubitemid 27052890)
30. Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, et al.Reduction of stroke events with Pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001;103(3):387-392 (Pubitemid 32105978)
31. Candelise L, Vigotti M, Fieschi C, Brambilla GL, Bono G, Conforti P, et al.Italian multicenter study on reversible cerebral ischemic attacks: VI - prognostic factors and follow-up results. Stroke 1986;17(5):842-848 [MEDLINE: 87020005] (Pubitemid 16000715)
32. Crouse JR 3rd, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Archives of Internal Medicine 1997;157(12):1305-1310 [MEDLINE: 97344622]
33. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278 [MEDLINE: 95282720]
34. Di Mascio R, Marchioli R, Tognoni G. Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials. Cerebrovacular Diseases 2000;10:85-92. (Pubitemid 30107501)
35. Dyker AG, Weir CJ, Lees KR. Influence of cholesterol on survival after stroke: retrospective study. BMJ 1997;314:1584-1588 [MEDLINE: 97329696]
36. Eliasziw M, Streifler JY, Spence JD, Fox AJ, Hachinski VC, Barnett HJM. Prognosis for patients following a transient ischemic attack with and without a cerebral infarction on brain CT. Neurology 1995;45:428-431 [MEDLINE: 95206518]
37. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in easternAsia. Lancet 1998;352:1801-1807
38. Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Archives of Internal Medicine 1995;155(1):50-55 [MEDLINE: 95100811]
39. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. Journal of the American Medical Association 1997;278(4):313-321 [MEDLINE: 97372174]
40. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91 Suppl 5:v1-52.
41. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study. Neurology 1997;48:891-895 [MEDLINE: 97264001] (Pubitemid 27175611)
42. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2004;326:1423-1429
43. Marshall J, Kaeser AC. Survival after non-haemorrhagic cerebrovascular accidents: a prospective study. British Medical Journal 1961:73-77
44. McNaughton H. Lowering lipids after a stroke or transient ischaemic attack. Hospital Medicine 2002;63(2):88-91.
45. Mendez I, Hachinski V, Wolfe B. Serumlipids after stroke. Neurology 1987;37:507-511 [MEDLINE: 87145065]
46. Moroney JT, Bagiella E, Tatemichi TK, Paik MC, Stern Y, Desmond DW. Dementia after stroke increases the risk of long-term stroke recurrence. Neurology 1997;48:1317-1325 [MEDLINE: 97297833] (Pubitemid 27240556)
47. Neau J-P, Ingrand P, Couderq C, Rosier MP, Bailbe M, Dumas P, et al.Recurrent intracerebral hemorrhage. Neurology 1997;49:106-113 [MEDLINE: 97365340]
48. Passero S, Burgalassi L, D'Andrea P, Battistini N. Recurrence of bleeding in patients with primary intracerebral hemorrhage. Stroke 1995;26(7):1189-1192 [MEDLINE: 95328103]
49. Prencipe M, Culasso F, Rasura M, Anzini A, Beccia M, Cao M, et al.Long-term prognosis after a minor stroke. 10-year mortality and major stroke recurrence rates in a hospital-based cohort. Stroke 1998;29:126-132 [MEDLINE: 98106118] (Pubitemid 28046953)
50. Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al.Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630 (Pubitemid 35379733)
51. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths. Lancet 2007;370:1829-1839
52. The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2008.
53. Sandercock P. Statins for stroke prevention?. Lancet 2001;357:1548-1549
54. Sorensen PS, Marquardsen J, Pedersen H, Heltberg A, Munck O. Long-term prognosis and quality of life after reversible cerebral ischemic attacks. Acta Neurologica Scandinavica 1989;79:204-213 [MEDLINE: 89244104] (Pubitemid 19076992)
55. van Latum JC, Koudstaal PJ, Venables GS, van Gijn J, Kappelle LJ, Algra A. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with non-rheumatic atrialfibrillation. Stroke 1995;26(5):801-806 [MEDLINE: 95259107]
56. Vauthey C, de Freitas GR, van Melle G, Devuyst G, Bogousslavsky J. Better outcome after stroke with higher serum cholesterol levels. Neurology 2000;54(10):1944-1949 (Pubitemid 30327117)
57. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al.Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. Journal of Human Hypertension 2004;18(3):139-185 (Pubitemid 38425770)
58. Wood D, Durrington P, McInnes, Paulter N, Rees A, Wray R. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80 Suppl 2:S1-29. (Pubitemid 29046520)
59. Manktelow BN, Gillies C, Potter J. Interventions in themanagement of serum lipids for preventing stroke recurrence. Cochrane Database of Systematic Reviews 2002, Issue 3. [Art. No.: CD002091. DOI: 10.1002/14651858.CD002091]